Name: Serdemetan (JNJ-26854165)
Brand: Selleck Chemicals
SKU: S1172
Rating: 5 (12 reviews)

Serdemetan (JNJ-26854165) Chemical Structure

CAS No. 881202-45-5

Selleck's Serdemetan (JNJ-26854165) has been cited by 12 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Related Compound Libraries

Other p53 Products

Download Inhibitor Catalog

p53 Signaling Pathway Map

Biological Activity

Description

Serdemetan (JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

KU-19-19 cell	NYK0W\|hlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlWwTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTN{M{[g{txO	MUDTRW5ITVJ?
H4 cell	NV7lVJdQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYnJdIJ2UW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFY4ODdizszN	M3yxZXNCVkeHUh?=
KGN cell	NIPGb21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYPLd4w4UW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN	NUjaU5pkW0GQR1XS
786-0 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NGXaZYNKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44Ojl6OTFOwG0>	NXT2V\|F1W0GQR1XS
769-P cell	NYq4bnI2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVj3T5pxUW6qaXLpeIlwdiCxZjDoeY1idiB5NkmtVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDJ{MkSg{txO	NI\4cGJUSU6JRWK=
K5 cell	M3jBXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV\CZ5RsUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFE3OjRizszN	M2HJenNCVkeHUh?=
MLMA cell	M1LJVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX\pfHVvUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB\|MkG3JO69VQ>?	M1zHOHNCVkeHUh?=
MLMA cell	MnPRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4X2U2lvcGmkaYTpc44hd2ZiaIXtZY4hVUyPQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlg4ODNizszN	MnHQV2FPT0WU
EW-7 cell	M3\sSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIrJToRKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlMzPjl3IN88US=>	M1;DXXNCVkeHUh?=
SW1088 cell	MmDuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFA3PTFizszN	M4[3TnNCVkeHUh?=
MC-IXC cell	M3vUdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NH72cplKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO	M4DvbXNCVkeHUh?=
NCI-H2052 cell	Mk\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVG5VlAxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxPTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkC4NVU4KM7:TR?=	M{jLeXNCVkeHUh?=
IGR-1 cell	NGnUfHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnXuTY5pcWKrdHnvckBw\iCqdX3hckBKT1JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNVIxOjhizszN	NH;LdmRUSU6JRWK=
DSH1 cell	MnzSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmTnTY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6yOFI6PiEQvF2=	M4jLXnNCVkeHUh?=
PA-1 cell	MkfrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3TvXGlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuN\|AxPToQvF2=	NVfLVFNtW0GQR1XS
SK-MEL-3 cell	Mm\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OTJyNzFOwG0>	NVXSdG92W0GQR1XS
SW900 cell	NV6xfmV2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlvqTY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOFgzPTVizszN	NVfncXAyW0GQR1XS
CAKI-1 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{G5[2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{42Ojd\|ODFOwG0>	NUnBXZQyW0GQR1XS
ES1 cell	M{\TNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF;jNI1KdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVI5QTdizszN	MWPTRW5ITVJ?
SK-N-DZ cell	M{L2cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnTnTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVTaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43OjV7NTFOwG0>	NFvyW5NUSU6JRWK=
RH-1 cell	NHOyUmxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MojoTY5pcWKrdHnvckBw\iCqdX3hckBTUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz62PFQ3OyEQvF2=	M4HMR3NCVkeHUh?=
ES8 cell	M2DqTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4jwZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz62PVcxOiEQvF2=	MWXTRW5ITVJ?
NEC8 cell	MkPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFPoe4pKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc3QTh{IN88US=>	NXW2T3lrW0GQR1XS
LNCaP-Clone-FGC cell	M1TlfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MknCTY5pcWKrdHnvckBw\iCqdX3hckBNVkOjUD3DcI9v\S2IR1OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg{PTN4IN88US=>	MmjMV2FPT0WU
HCE-4 cell	MmrVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXLjd\|czUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0>	MYjTRW5ITVJ?
U-118-MG cell	NFXJT2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHTK[ZBKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1?	MUjTRW5ITVJ?
GI-ME-N cell	NUCzPFd{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2HIeGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvTVWtUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODh5OU[g{txO	NGGwR\|FUSU6JRWK=
LB1047-RCC cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWjZSHpZUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xOlE1OyEQvF2=	MYPTRW5ITVJ?
HT-1080 cell	NVz6WFY{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE6QTJzIN88US=>	MXHTRW5ITVJ?
NB69 cell	NX;Nb4tOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmC5TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6zOVA1PyEQvF2=	MnizV2FPT0WU
NCI-H1693 cell	NFXtSWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4XNXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52NEi5OUDPxE1?	NH3aWW5USU6JRWK=
HSC-3 cell	NXKxboh2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60PVk{OyEQvF2=	MmG3V2FPT0WU
MDA-MB-231 cell	M4jUN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4DvNmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwNUW4PVkh\|ryP	MVnTRW5ITVJ?
HOS cell	M3:5R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmjFTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke4OlMh\|ryP	NYfMUnBNW0GQR1XS
BT-549 cell	M{DJfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGJVNTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|g5PyEQvF2=	Mn7yV2FPT0WU
NB17 cell	NXu1SYc2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYPTcFNVUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0>	M2PQSHNCVkeHUh?=
5637 cell	MoDtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3i4[GlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|k3PTJizszN	M4fTR3NCVkeHUh?=
OVCAR-8 cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{DyRmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTJ2M{[g{txO	NFKyU\|hUSU6JRWK=
G-402 cell	NG\BcWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND65N\|A{PSEQvF2=	Mkf4V2FPT0WU
BB30-HNC cell	NH73bWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYnkVHltUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwMEeyNVgh\|ryP	M33VOnNCVkeHUh?=
HCC1806 cell	Mn;rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFX6XZFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G4NFYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjB6M{O5JO69VQ>?	M1HufHNCVkeHUh?=
COLO-800 cell	NGHQb\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVPJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOECwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yOjZ2IN88US=>	NEHiboxUSU6JRWK=
FADU cell	M3jCT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NH\IN2lKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM3PTV5IN88US=>	NEX1cXpUSU6JRWK=
NCI-H1651 cell	MkO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1;jVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5\|OUSwPUDPxE1?	NFHLWINUSU6JRWK=
AGS cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWnUNnJ3UW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=>	MX\TRW5ITVJ?
CHP-212 cell	MmjpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NV\XbHNrUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5\|OUSwPUDPxE1?	M{G1bXNCVkeHUh?=
YAPC cell	NWnHRYkxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NG\VenhKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=>	M1vmS3NCVkeHUh?=
GOTO cell	NIjyR2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnzlTY5pcWKrdHnvckBw\iCqdX3hckBIV1SRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60PVU4PiEQvF2=	M3G0XHNCVkeHUh?=
KYSE-510 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXfJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OTFizszN	MlzoV2FPT0WU
NCI-H2342 cell	NGnLcodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmHnTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV\|Mke4JO69VQ>?	NUjTVZdyW0GQR1XS
BFTC-905 cell	MoHUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh\|NTFOwG0>	NETIWpNUSU6JRWK=
EW-16 cell	M17ZbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4ewN2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODl\|IN88US=>	M1H0[3NCVkeHUh?=
SK-MEL-30 cell	MlLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUnPW\|RzUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke0OVQ{KM7:TR?=	MkjIV2FPT0WU
HLE cell	NGLKUIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFrhU4tKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|c1QDlizszN	Mo\MV2FPT0WU
T98G cell	Moj5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF23SItKdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6PjN3IN88US=>	MWTTRW5ITVJ?
HUTU-80 cell	NEL1boRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3HQb2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDR{Mkig{txO	NUDiUmR[W0GQR1XS
NOS-1 cell	M3f3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3fOVmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk1PzZ4IN88US=>	M1TOTnNCVkeHUh?=
SW780 cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkTWTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVY6PDlizszN	NELBOJdUSU6JRWK=
KYSE-180 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWX3dXQ4UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe2OVQh\|ryP	NW\QOJpNW0GQR1XS
MDA-MB-361 cell	NIPkdXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl6NkS3JO69VQ>?	MlfDV2FPT0WU
SNU-C2B cell	M33rSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{TvUGlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLVOyRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODFzM{ig{txO	NHe5W5pUSU6JRWK=
NCI-H661 cell	NXvEfnZIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVrlS5MzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwME[5OEDPxE1?	M1;qV3NCVkeHUh?=
OE33 cell	NYjTcYE2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3y3[mlvcGmkaYTpc44hd2ZiaIXtZY4hV0V\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNVQ{QDlizszN	NY\FfFBoW0GQR1XS
TYK-nu cell	NUnHdnhuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkXJTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ\|IN88US=>	MmPqV2FPT0WU
COLO-792 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUT3PJhGUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMkWyNVkh\|ryP	NXv0dWlvW0GQR1XS
HEL cell	M4rJPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M37TPWlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj6yOlc3KM7:TR?=	MUDTRW5ITVJ?
D-566MG cell	NXy5T\|hST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYTEZlE{UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5\|M{S5NUDPxE1?	MYjTRW5ITVJ?
U031 cell	NEfhbGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWjKTHhvUW6qaXLpeIlwdiCxZjDoeY1idiCXMEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OThzNjFOwG0>	Mn3pV2FPT0WU
COR-L23 cell	NYLoW2RvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2fn[mlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPDN\|NE[g{txO	M33tc3NCVkeHUh?=
NCI-H2452 cell	Ml;kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX[yVIpQUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1PTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkWyNlgyKM7:TR?=	MVHTRW5ITVJ?
BB65-RCC cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PDV7IN88US=>	Mo\WV2FPT0WU
CAL-33 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVG5W2hZUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ3Nk[1JO69VQ>?	MUjTRW5ITVJ?

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p53 / HDM2 / HDMX / p21 / Noxa / Puma ; ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; MDM2 / p-MDM2 / p53 ; Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3	20736344 23820125 27999193
Growth inhibition assay	Cell viability	23820125
Immunofluorescence	p53	27999193

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol (from reference)

Cell Research:^[1]

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

Animal Models: CB17SC scid^-/- female mice.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

+ Expand

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Water	Insoluble
	Ethanol	'2 mg/mL
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing. Click to purchase: Tween 80	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4

Download Serdemetan (JNJ-26854165) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00676910	Completed	Drug: JNJ-26854165	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):